Congestive heart failure treatment of patients with current or prior symptoms of heart failure (Stage C): Difference between revisions
(New page: {{Infobox_Disease | Name = Heart failure | Image = | Caption = | DiseasesDB = 16209 | ICD10 = {{ICD10|I|50|0|i|50}} | ICD9 = {{...) |
No edit summary |
||
Line 25: | Line 25: | ||
{{cquote| | {{cquote| | ||
===Class I=== | ===Class I=== | ||
1. Measures listed as Class I recommendations for patients in stages A and B are also appropriate for patients in Stage C. (Levels of Evidence: A, B, and C as appropriate) | 1. Measures listed as Class I recommendations for patients in [[Congestive heart failure treatment of patients at high risk for developing heart failure (Stage A)|stages A]] and [[Congestive heart failure treatment of patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)|B]] are also appropriate for patients in Stage C. ''(Levels of Evidence: A, B, and C as appropriate)'' | ||
2. Diuretics and salt restriction are indicated in patients with current or prior symptoms of HF and reduced LVEF who have evidence of fluid retention. (Level of Evidence: C) | 2. [[Diuretics]] and [[salt]] restriction are indicated in patients with current or prior symptoms of [[HF]] and reduced [[LVEF]] who have evidence of [[fluid retention]]. ''(Level of Evidence: C)'' | ||
3. Angiotensin converting enzyme inhibitors are recommended for all patients with current or prior symptoms of HF and reduced LVEF, unless contraindicated. (Level of Evidence: A) | 3. [[Angiotensin converting enzyme inhibitors]] are recommended for all patients with current or prior symptoms of [[HF]] and reduced [[LVEF]], unless contraindicated. ''(Level of Evidence: A)'' | ||
4. Beta-blockers (using 1 of the 3 proven to reduce mortality, i.e., bisoprolol, carvedilol, and sustained release metoprolol succinate) are recommended for all stable patients with current or prior symptoms of HF and reduced LVEF, unless contraindicated. (Level of Evidence: A) | 4. [[Beta-blockers]] (using 1 of the 3 proven to reduce mortality, i.e., [[bisoprolol]], [[carvedilol]], and sustained release [[metoprolol succinate]]) are recommended for all stable patients with current or prior symptoms of [[HF]] and reduced [[LVEF]], unless contraindicated. ''(Level of Evidence: A)'' | ||
5. Angiotensin II receptor blockers approved for the treatment of HF are recommended in patients with current or prior symptoms of HF and reduced LVEF who are ACEI-intolerant (as in patients with angioedema). (Level of Evidence: A) | 5. [[Angiotensin II receptor blockers]] approved for the treatment of [[HF]] are recommended in patients with current or prior symptoms of [[HF]] and reduced [[LVEF]] who are [[ACEI]]-intolerant (as in patients with [[angioedema]]). ''(Level of Evidence: A)'' | ||
6. Drugs known to adversely affect the clinical status of patients with current or prior symptoms of HF and reduced LVEF should be avoided or withdrawn whenever possible (e.g., non steroidal anti-inflammatory drugs, most antiarrhythmic drugs, and most calcium channel blocking drugs; see text). (Level of Evidence: B) | 6. Drugs known to adversely affect the clinical status of patients with current or prior symptoms of [[HF]] and reduced [[LVEF]] should be avoided or withdrawn whenever possible (e.g., [[non steroidal anti-inflammatory drugs]], most [[antiarrhythmic drugs]], and most [[calcium channel blocking drugs]]; see text). ''(Level of Evidence: B)'' | ||
7. Exercise training is beneficial as an adjunctive approach to improve clinical status in ambulatory patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: B) | 7. Exercise training is beneficial as an adjunctive approach to improve clinical status in ambulatory patients with current or prior symptoms of [[HF]] and reduced [[LVEF]]. ''(Level of Evidence: B)'' | ||
8. An implantable cardioverter-defibrillator is recommended as secondary prevention to prolong survival in patients with current or prior symptoms of HF and reduced LVEF who have a history of cardiac arrest, ventricular fibrillation, or hemodynamically destabilizing ventricular tachycardia. (Level of Evidence: A) | 8. An [[implantable cardioverter-defibrillator]] is recommended as secondary prevention to prolong survival in patients with current or prior symptoms of [[HF]] and reduced [[LVEF]] who have a history of [[cardiac arrest]], [[ventricular fibrillation]], or hemodynamically destabilizing [[ventricular tachycardia]]. ''(Level of Evidence: A)'' | ||
9. Implantable cardioverter-defibrillator therapy is recommended for primary prevention to reduce total mortality by a reduction in sudden cardiac death in patients with ischemic heart disease who are at least 40 days post-MI, have an LVEF less than or equal to 30%, with NYHA functional class II or III symptoms while undergoing chronic optimal medical therapy, and have reasonable expectation of survival with a good functional status for more than 1 year. (Level of Evidence: A) | 9. [[Implantable cardioverter-defibrillator]] therapy is recommended for primary prevention to reduce total mortality by a reduction in [[sudden cardiac death]] in patients with [[ischemic heart disease]] who are at least 40 days post-[[MI]], have an [[LVEF]] less than or equal to 30%, with NYHA functional class II or III symptoms while undergoing chronic optimal medical therapy, and have reasonable expectation of survival with a good functional status for more than 1 year. ''(Level of Evidence: A)'' | ||
10. Implantable cardioverter-defibrillator therapy is recommended for primary prevention to reduce total mortality by a reduction in sudden cardiac death in patients with non ischemic cardiomyopathy who have an LVEF less than or equal to 30%, with NYHA functional class II or III symptoms while undergoing chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 year. (Level of Evidence: B) | 10. [[Implantable cardioverter-defibrillator]] therapy is recommended for primary prevention to reduce total mortality by a reduction in [[sudden cardiac death]] in patients with [[non ischemic cardiomyopathy]] who have an [[LVEF]] less than or equal to 30%, with NYHA functional class II or III symptoms while undergoing chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 year. ''(Level of Evidence: B)'' | ||
11. Patients with LVEF less than or equal to 35%, sinus rhythm, and NYHA functional class III or ambulatory class IV symptoms despite recommended, optimal medical therapy and who have cardiac dyssynchrony, which is currently defined as a QRS duration greater than 0.12 ms, should receive cardiac resynchronization therapy unless contraindicated. (Level of Evidence: A) | 11. Patients with [[LVEF]] less than or equal to 35%, sinus rhythm, and NYHA functional class III or ambulatory class IV symptoms despite recommended, optimal medical therapy and who have cardiac dyssynchrony, which is currently defined as a QRS duration greater than 0.12 ms, should receive [[cardiac resynchronization therapy]] unless contraindicated. ''(Level of Evidence: A)'' | ||
12. Addition of an aldosterone antagonist is reasonable in selected patients with moderately severe to severe symptoms of HF and reduced LVEF who can be carefully monitored for preserved renal function and normal potassium concentration. Creatinine should be less than or equal to 2.5 mg/dL in men or less than or equal to 2.0 mg/dL in women and potassium should be less than 5.0 mEq/L. Under circumstances where monitoring for hyperkalemia or renal dysfunction is not anticipated to be feasible, the risks may outweigh the benefits of aldosterone antagonists. (Level of Evidence: B)'' | 12. Addition of an [[aldosterone antagonist]] is reasonable in selected patients with moderately severe to severe symptoms of [[HF]] and reduced [[LVEF]] who can be carefully monitored for preserved renal function and normal [[potassium]] concentration. [[Creatinine]] should be less than or equal to 2.5 mg/dL in men or less than or equal to 2.0 mg/dL in women and [[potassium]] should be less than 5.0 mEq/L. Under circumstances where monitoring for [[hyperkalemia]] or [[renal dysfunction]] is not anticipated to be feasible, the risks may outweigh the benefits of [[aldosterone antagonists]]. ''(Level of Evidence: B)'' | ||
===Class IIa=== | ===Class IIa=== |
Revision as of 15:00, 10 June 2009
Heart failure | |
ICD-10 | I50.0 |
---|---|
ICD-9 | 428.0 |
DiseasesDB | 16209 |
MedlinePlus | 000158 |
eMedicine | med/3552 |
MeSH | D006333 |
WikiDoc Resources for Congestive heart failure treatment of patients with current or prior symptoms of heart failure (Stage C) |
Articles |
---|
Media |
Evidence Based Medicine |
Clinical Trials |
|
Guidelines / Policies / Govt |
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
|
Healthcare Provider Resources |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Cardiology Network |
Discuss Congestive heart failure treatment of patients with current or prior symptoms of heart failure (Stage C) further in the WikiDoc Cardiology Network |
Adult Congenital |
---|
Biomarkers |
Cardiac Rehabilitation |
Congestive Heart Failure |
CT Angiography |
Echocardiography |
Electrophysiology |
Cardiology General |
Genetics |
Health Economics |
Hypertension |
Interventional Cardiology |
MRI |
Nuclear Cardiology |
Peripheral Arterial Disease |
Prevention |
Public Policy |
Pulmonary Embolism |
Stable Angina |
Valvular Heart Disease |
Vascular Medicine |
Template:WikiDoc Cardiology News Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview of Treatment of Patients With Current or Prior Symptoms of Heart Failure (Stage C)
ACC / AHA Guidelines- Patients with Reduced LVEF (DO NOT EDIT) [1]
“ |
Class I1. Measures listed as Class I recommendations for patients in stages A and B are also appropriate for patients in Stage C. (Levels of Evidence: A, B, and C as appropriate) 2. Diuretics and salt restriction are indicated in patients with current or prior symptoms of HF and reduced LVEF who have evidence of fluid retention. (Level of Evidence: C) 3. Angiotensin converting enzyme inhibitors are recommended for all patients with current or prior symptoms of HF and reduced LVEF, unless contraindicated. (Level of Evidence: A) 4. Beta-blockers (using 1 of the 3 proven to reduce mortality, i.e., bisoprolol, carvedilol, and sustained release metoprolol succinate) are recommended for all stable patients with current or prior symptoms of HF and reduced LVEF, unless contraindicated. (Level of Evidence: A) 5. Angiotensin II receptor blockers approved for the treatment of HF are recommended in patients with current or prior symptoms of HF and reduced LVEF who are ACEI-intolerant (as in patients with angioedema). (Level of Evidence: A) 6. Drugs known to adversely affect the clinical status of patients with current or prior symptoms of HF and reduced LVEF should be avoided or withdrawn whenever possible (e.g., non steroidal anti-inflammatory drugs, most antiarrhythmic drugs, and most calcium channel blocking drugs; see text). (Level of Evidence: B) 7. Exercise training is beneficial as an adjunctive approach to improve clinical status in ambulatory patients with current or prior symptoms of HF and reduced LVEF. (Level of Evidence: B) 8. An implantable cardioverter-defibrillator is recommended as secondary prevention to prolong survival in patients with current or prior symptoms of HF and reduced LVEF who have a history of cardiac arrest, ventricular fibrillation, or hemodynamically destabilizing ventricular tachycardia. (Level of Evidence: A) 9. Implantable cardioverter-defibrillator therapy is recommended for primary prevention to reduce total mortality by a reduction in sudden cardiac death in patients with ischemic heart disease who are at least 40 days post-MI, have an LVEF less than or equal to 30%, with NYHA functional class II or III symptoms while undergoing chronic optimal medical therapy, and have reasonable expectation of survival with a good functional status for more than 1 year. (Level of Evidence: A) 10. Implantable cardioverter-defibrillator therapy is recommended for primary prevention to reduce total mortality by a reduction in sudden cardiac death in patients with non ischemic cardiomyopathy who have an LVEF less than or equal to 30%, with NYHA functional class II or III symptoms while undergoing chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 year. (Level of Evidence: B) 11. Patients with LVEF less than or equal to 35%, sinus rhythm, and NYHA functional class III or ambulatory class IV symptoms despite recommended, optimal medical therapy and who have cardiac dyssynchrony, which is currently defined as a QRS duration greater than 0.12 ms, should receive cardiac resynchronization therapy unless contraindicated. (Level of Evidence: A) 12. Addition of an aldosterone antagonist is reasonable in selected patients with moderately severe to severe symptoms of HF and reduced LVEF who can be carefully monitored for preserved renal function and normal potassium concentration. Creatinine should be less than or equal to 2.5 mg/dL in men or less than or equal to 2.0 mg/dL in women and potassium should be less than 5.0 mEq/L. Under circumstances where monitoring for hyperkalemia or renal dysfunction is not anticipated to be feasible, the risks may outweigh the benefits of aldosterone antagonists. (Level of Evidence: B) Class IIaClass IIbClass III |
” |
See Also
Sources
- The ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult [1]
References
- ↑ 1.0 1.1 Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005 Sep 20; 112(12): e154-235. Epub 2005 Sep 13. PMID 16160202